Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

This study investigated the impact of the JAK inhibitor ruxolitinib on APS-1 patients, reporting that treatment decreased excessive T-cell-derived interferon-γ, normalized inflammatory markers, and led to remission of several autoimmune symptoms without serious adverse effects.

This review discusses how tissue resident memory T cells contribute to autoimmune skin diseases like vitiligo and psoriasis, highlighting their role in continuous immune activation, and reports no new clinical results.

This study identified a novel G207E STING mutation associated with severe inflammatory symptoms and suggested that common polymorphisms in TMEM173 and IFIH1 may modify the phenotype in affected individuals.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This study found that topical ruxolitinib protected Lgr5+ skin stem cells and maintained skin homeostasis in skin GVHD, unlike corticosteroids.

This review summarizes the pathophysiology and immune mechanisms of inflammatory skin diseases like psoriasis and atopic dermatitis, highlighting the therapeutic potential of targeted immunotherapies, but reports no new clinical results.

This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

This study found that topical curcumin can initiate hair growth in mice by acting as a JAK inhibitor but could not fully reverse alopecia areata, likely due to insufficient penetration to deeper skin layers.

This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.

This review discusses current and emerging therapies for alopecia areata, highlighting unmet therapeutic needs and the psychosocial burden on patients but reports no new clinical results.

JAK inhibitors are effective for hair regrowth in severe alopecia areata.

This bibliometric analysis reported a significant increase in publications on hair loss treatments since 2001, highlighting new focuses on non-invasive regenerative therapies like platelet-rich plasma, microneedling, and JAK inhibitors, but emphasized the need for further high-quality clinical trials to confirm their effectiveness.

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

This review in JEADV highlights the systemic causes of hair loss, emphasizing the psychosocial impact of androgenetic alopecia and exploring post-COVID-19 telogen effluvium, while also addressing the treatment safety and challenges in alopecia areata management.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This article reviews key developments in pediatric dermatology for 2017, including consensus recommendations, novel genetic findings, and treatment insights for conditions like psoriasis and vascular malformations, without providing new clinical trial results.

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This quiz presents educational questions about alopecia areata, including its diagnosis and underlying mechanisms, but reports no new clinical outcomes.

This article discusses various aspects of hair loss but reports no new research findings.

This study reported that topical drugs regrew hair in mice.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

This case report describes a rare occurrence of a solitary fibrofolliculoma in the right lower eyelid of a 50-year-old man, confirmed through histopathological examination.

This review discusses the pharmacology and potential therapeutic effects of rare ginsenoside compound K on metabolic disorders but presents no new clinical results, highlighting the need for further studies on its bioavailability and toxicity.

This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.